Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US10167312B2 · kind B2 · utility
2Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2017 |
| Grant date | Jan 1, 2019 |
| Priority date | — |
| Expiry date | Oct 20, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/723
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.